We Lost Our Beloved Ones in COVID-19: Reasons revealed
How Funding Cycles and Scientific Priorities Shape Pandemic Preparedness: Lessons from SARS to COVID-19
Scientific progress in infectious disease research is deeply influenced not only by discovery but also by funding priorities. The way agencies such as the National Institutes of Health (NIH) allocate resources plays a critical role in determining which pathogens are studied continuously and which are addressed only during crises. The history of coronavirus research, particularly following the 2002–2004 SARS outbreak, illustrates this dynamic clearly.
The 2002–2003 SARS Outbreak and Rapid Scientific Response
COVID-19 was preceded by earlier coronavirus outbreaks, including Severe Acute Respiratory Syndrome (SARS), caused by SARS-CoV, which emerged in late 2002 and spread globally in 2003. The outbreak triggered an urgent international scientific response. Within months, researchers identified the virus, sequenced its genome, and began developing diagnostic tests and experimental vaccines.
Key contributors to this rapid response included scientists such as Ralph S. Baric, Malik Peiris, Christian Drosten, and Yoshihiro Kawaoka, among others. Their work laid the foundation for understanding coronavirus biology, host–pathogen interactions, and viral transmission mechanisms.
During this period, the NIH—primarily through the National Institute of Allergy and Infectious Diseases (NIAID)—supported coronavirus research, although funding levels fluctuated after the outbreak subsided.
What Happened After SARS Was Contained
By 2004, SARS transmission had been contained. Without ongoing outbreaks, SARS-specific funding opportunities declined significantly. Instead, NIH resources increasingly focused on other priority areas, including HIV/AIDS, cancer biology, neurodegenerative diseases, and influenza preparedness.
Many researchers who had worked on SARS transitioned to broader areas of virology, such as general coronavirus research, emerging infectious diseases, or biodefense-related work. For example, long-term investigators like Ralph Baric continued to receive NIH support for broader coronavirus and RNA virus studies, even as SARS-specific grants became less common.
This reflects a structural feature of biomedical funding systems: sustained investment is often strongest for diseases perceived as ongoing threats, while interest in contained outbreaks tends to decline over time.
Implications for COVID-19 and Future Pandemics
The emergence of SARS-CoV-2 in 2019 again demonstrated the consequences of this reactive model. Although foundational work on SARS-CoV and related coronaviruses had been conducted in the early 2000s, sustained large-scale investment in coronavirus vaccine platforms and antivirals was limited in the years between SARS and COVID-19.
When COVID-19 emerged, scientists were able to respond rapidly because prior knowledge of SARS and MERS existed. However, the lack of continuous, high-level investment in coronavirus countermeasures meant that much of the response had to occur under emergency conditions, despite earlier scientific warnings about pandemic potential.
Conclusion: Toward Sustained Preparedness
The history of SARS research illustrates an important principle in biomedical science: scientific attention does not always align with long-term risk. Funding systems that respond primarily to immediate threats can generate rapid breakthroughs during crises but may underinvest in sustained preparedness.
Strengthening global preparedness for future pandemics may require more stable, long-term investment in high-risk viral families, even during periods when they appear to be under control.
In an interconnected world, pathogens do not remain confined by the timelines of funding cycles. Scientific preparedness depends not only on reacting to outbreaks, but also on maintaining attention to them after they fade.
